Drugs / PE-E7-K3
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01880411 | Jun 2013 → Jan 2014 | cervical intraepithelial neoplasia | HealthBanks Biotech Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PE-E7-K3 | “PEK (PE-E7-K3), a recombinant protein combined with GPI-0100 adjuvant” NCT01880411 ↗ |
| Known as | PEK | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01880411 ↗ |